| TOPIGEN PHARMACEUTICALS INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120065249 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING ALLERGY AND NEOPLASTIC CELL PROLIFERATION - Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors. | 03-15-2012 |
| 20110086901 | OLIGONUCLEOTIDES AFFECTING EXPRESSION OF PHOSPHODIESTERASES - The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial. | 04-14-2011 |
| 20100048673 | OLIGONUCLEOTIDES AFFECTING EXPRESSION OF PHOSPHODIESTERASES - The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial. | 02-25-2010 |
| 20090298913 | SMALL INTERFERING OLIGONUCLEOTIDES COMPRISING ARABINOSE MODIFIED NUCLEOTIDES - Small interfering ribonucleic acid duplexes that inhibit gene expression containing at least one arabinose modified nucleotide are provided. Preferably, the duplexes contain ribonucleotides at least one arabinose modified nucleotide is 2′-deoxy-2′-fluoroarabinonucleotide (FANA) nucleotide. | 12-03-2009 |
| 20090215861 | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation - Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors. | 08-27-2009 |
| 20090088411 | No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties - There are herein provided methods of treatment and nitric oxide donating compositions of matter for the treatment of respiratory diseases and associated conditions. | 04-02-2009 |
| 20090087425 | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease - There is provided a pharmaceutical composition for treating respiratory disease comprising an NO-donating steroid and at least one bronchodilator. Also provided is a method for treating respiratory diseases associated with inflammation comprising administering an NO-donating steroid with at least one bronchodilator. Method of use of the combination of an NO-donating compound, and a steroid with at least one bronchodilator for treating respiratory disease is also provided. | 04-02-2009 |
| 20090020602 | METHOD FOR ESTABLISHING A SECURE LOGICAL CONNECTION BETWEEN AN INTEGRATED CIRCUIT CARD AND A MEMORY CARD THROUGH A TERMINAL EQUIPMENT - A user system includes terminal equipment, a removable integrated circuit card and a removable memory card configured to cooperate with the terminal equipment, a card link application provided in the integrated circuit card to establish and manage a secure logical connection between the integrated circuit card and the memory card through the terminal equipment, and an application programming interface provided in the terminal equipment to receive and execute commands from the card link application and to cooperate with the card link application to establish the secure logical connection between the integrated circuit card and the memory card through the first terminal equipment. | 01-22-2009 |
